HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Finalizes Guidance On Blood Glucose Meters With Separate Documents For OTC, Rx Devices

Executive Summary

The documents issued by the US agency on 29 September set slightly different accuracy standards, reflecting the increased fragility of hospital patients.

You may also be interested in...



US FDA Redrafts Glucose Meter Guidances With Small Updates

The agency finalized two parallel guidance documents in 2016 relating to hospital point-of-care and patient over-the-counter use of blood glucose meters. But it has now reissued the documents in draft form to make what an agency spokeswoman referred to as "mostly minor" changes.

FDA’s Biotin Interference Guidance Finalized

The document recommends testing for blood biotin levels as high as 3500 ng/mL, three times the maximum expected clinical concentration.

Merit Medical To Pay $18M To Settle Kickback Case

The US Department of Justice says the company provided advertising assistance and educational grants to health care providers that used its embolization devices.

UsernamePublicRestriction

Register

OM013057

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel